SEC Filings Reveal GlaxoSmithKline's 13% Stake in This Massachusetts Biotech Post author:Sam Post published:November 16, 2017 Post category:BioPharma A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics. Source: BioSpace You Might Also Like Seattle Genetics, Immunomedics Ink $2 Billion Tumor Drug Deal February 9, 2017 Keystone Nano Announces Start Of Clinical Testing Of Ceramide NanoLiposome For The Improved Treatment Of Cancer April 6, 2017 Agile Therapeutics, Inc. Announces A Poster Presentation Of Its SECURE Phase III Study At The Conference March 16, 2017
Keystone Nano Announces Start Of Clinical Testing Of Ceramide NanoLiposome For The Improved Treatment Of Cancer April 6, 2017
Agile Therapeutics, Inc. Announces A Poster Presentation Of Its SECURE Phase III Study At The Conference March 16, 2017